|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Changes in RET expression have been discovered in 30-70% of invasive breast cancers and 50-60% of pancreatic ductal adenocarcinomas in addition to colorectal adenocarcinoma, melanoma, small cell lung cancer, neuroblastoma, and small intestine neuroendocrine tumors.
|
31715421 |
2019 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
|
27635639 |
2017 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, RET is expressed in 18% of adenocarcinomas and all three small-cell carcinomas examined.<b>Conclusions:</b> RET promotes transformation associated phenotypes, including perineural invasion in prostate cancer via activation of p70S6 kinase.
|
28490466 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with RET rearranged adenocarcinomas represent a rare and heterogeneous NSCLC subgroup.
|
26762747 |
2016 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
RET fusions were identified in one adenocarcinoma, NOS (CCDC6-RET) and two SDCs (NCOA4-RET).
|
27334835 |
2016 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Strikingly, clinically relevant alterations in the receptor tyrosine kinase (RTK)/Ras signaling pathway including alterations in ALK, ARAF, BRAF, EGFR, FGFR1, FGFR2, KIT, KRAS, MAP2K1, MET, NF1, NF2, NRAS, RAF1, RET, and ROS1 were found in 90 (72%) ACUPs but in only 29 (39%) non-ACUPs (P < .001).
|
26182302 |
2015 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Cells with cytoplasmic mucin production were at least focally present in 12 of the 22 (54.5%) RET-rearranged ADC cases.
|
24504365 |
2014 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
However, clinically useful methods to detect RET-rearrangement in pulmonary adenocarcinoma have not been well established.
|
23932363 |
2013 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, we discovered previously unidentified kinase fusions that may be promising for molecular-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain containing 6 (CCDC6)-RET, in 14 adenocarcinomas.
|
22327623 |
2012 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Of 936 patients with NSCLC, the RET fusion gene was exclusively detected in 13 patients (11 of 633 patients with adenocarcinomas and two of 24 patients with adenosquamous cell carcinomas).
|
23150706 |
2012 |